Issue represents a potential threat in fighting future pandemics.
Kevin E. Noonan, PhD
Advertisement
Partner with IP law firm MBHB and the co-chair of its biotechnology and pharmaceuticals practice group
Articles by Kevin E. Noonan, PhD
Kevin E. Noonan asks, what do the biosimilars provisions of the Trans-Pacific Partnership portend for global biologic drug development?
Advertisement
Latest Updated Articles
Global Biologic Drug Development and the TTPPublished: January 25th 2016 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
